Takeda/Tigenix’ stem cell therapy hits targets in Crohn’s trial – PharmaTimes
PharmaTimes |
Takeda/Tigenix' stem cell therapy hits targets in Crohn's trial
PharmaTimes Takeda and TiGenix' stem cell therapy has shown promise in inducing remission of perianal fistulas in patients with Crohn's disease, according findings of a late-stage trial published in The Lancet. The Phase III ADMIRE-CD trial assessed the safety and … |
